Figure 5

Combinational therapy of nutlin-3 and geldanamycin in AML cells lines and primary AML cells. (A) MOLM-13 cells were treated with DMSO (control), nutlin-3 (5 μM), geldanamycin (0.5 μM) or the combination of nutlin-3 and geldanamycin for 24 hours and analyzed by Annexin-PI viability assay. Reduction of viability by the combinational treatment was compared to either compound alone (**p < 0.01, *p < 0.05). Results are from three independent experiments and error bars represent standard error of mean. Viability values determined by staining with Hoechst 33342 are given below the Annexin-PI data. (B) Synergism calculated by Bliss Independence analysis for results from Figure (A) showing expected and actual response for the combinational treatment (C) Sensitivity to nutlin-3 (5 μM), geldanamycin (0.5 μM), or the combination of both for 24 hours in AML cell lines MOLM-13, HL60, OCI-AML3, normal peripheral blood lymphocytes and 16 primary AML samples analyzed by Annexin-PI and visualized using TMEV microarray software, with corresponding clinical parameters for each of the patients. (D) Bliss Independence analysis of expected and actual response for the combinational therapy for each of the individual responding AML patient samples analyzed by Annexin-PI (n = 10).